Response Oncology, Inc. (ROIX) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Response Oncology, Inc. (ROIX) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Response Oncology, Inc. (ROIX) Gesundheitswesen & Pipeline-Uebersicht
Response Oncology, Inc., incorporated in 1984, previously offered advanced cancer treatment services, managed oncology practices, and compounded pharmaceuticals. Following the liquidation of its operating assets in 2002, the company has ceased significant operations and is based in Memphis, Tennessee.
Investmentthese
Response Oncology, Inc. presents a unique case for investors, given its historical context and current state. The company liquidated its operating assets in 2002 and has no significant operations as of 2026. With a market capitalization of $0.00B and a beta of -19.14, the stock's behavior may not align with typical market dynamics. Potential investors should carefully consider the implications of the company's dormant operational status and the absence of revenue-generating activities. Any investment decision should be based on a thorough understanding of the company's historical filings and any potential future plans, if disclosed.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap: $0.00B indicates the company has negligible market capitalization.
- Beta: -19.14 suggests the stock price moves inversely to the market, but this may not be reliable given the lack of operations.
- Liquidation of assets completed in 2002, marking a significant shift in the company's business model.
- No significant operations as of 2026, indicating a dormant business state.
- Employee count of 10 suggests minimal ongoing business activity.
Wettbewerber & Vergleichsunternehmen
Staerken
- Historical presence in cancer management.
- Established network of IMPACT Centers (prior to liquidation).
- Experience in pharmaceutical compounding.
- Conducted outcomes research.
Schwaechen
- No significant operations as of 2026.
- Liquidated substantially all operating assets in 2002.
- Lack of current revenue streams.
- Limited market presence.
Katalysatoren
- Ongoing: Potential for restructuring or acquisition by another company.
- Ongoing: Any future announcements regarding the company's plans or operations.
- Ongoing: Changes in the regulatory environment that could impact the company's prospects.
Risiken
- Potential: Lack of liquidity in the OTC market.
- Potential: Limited or no financial disclosure.
- Potential: High price volatility.
- Ongoing: The company has no significant operations.
- Ongoing: Uncertainty regarding the company's future plans.
Wachstumschancen
- Growth opportunity 1: Given that Response Oncology, Inc. has liquidated its operating assets and has no significant operations, traditional growth opportunities are not applicable. Any potential future growth would depend on a complete restructuring and a new business plan, which is not currently evident. The company would need to identify a new market, develop a viable business model, and secure funding to pursue any growth initiatives. This would essentially be a new venture under the same corporate shell.
- Growth opportunity 2: The company could explore opportunities in healthcare technology, leveraging any remaining intellectual property or expertise from its past operations. This would require significant investment in research and development, as well as a deep understanding of current market needs and technological trends. The market for healthcare technology is projected to reach $280 billion by 2028, presenting a substantial opportunity for a company with the right strategy and resources.
- Growth opportunity 3: Response Oncology could potentially re-enter the oncology care market by focusing on niche areas such as personalized medicine or telemedicine. This would require a strategic shift towards innovation and a focus on delivering specialized services to a targeted patient population. The personalized medicine market is expected to grow to $4.2 billion by 2027, offering a potential avenue for growth.
- Growth opportunity 4: The company could consider acquiring or merging with another healthcare company to gain access to new markets, technologies, or expertise. This would require careful due diligence and a clear understanding of the strategic fit between the two organizations. The healthcare industry is undergoing consolidation, with numerous mergers and acquisitions occurring each year, presenting opportunities for companies to expand their reach and capabilities.
- Growth opportunity 5: Response Oncology could explore opportunities in the development of new cancer therapies or diagnostic tools. This would require significant investment in research and development, as well as a strong understanding of the regulatory landscape and the clinical trial process. The market for cancer therapies is projected to reach $200 billion by 2027, offering a substantial opportunity for companies that can develop innovative treatments.
Chancen
- Potential for restructuring and re-entry into the healthcare market.
- Leveraging historical expertise in oncology care.
- Exploring opportunities in healthcare technology.
- Acquiring or merging with another healthcare company.
Risiken
- Competition from established healthcare providers.
- Evolving regulatory landscape in the healthcare industry.
- Difficulty in securing funding for new ventures.
- Risk of obsolescence due to technological advancements.
Wettbewerbsvorteile
- Historically, the company's network of IMPACT Centers provided a degree of geographic advantage.
- Relationships with practicing oncologists offered a competitive edge in patient referrals.
- In-house pharmaceutical compounding provided cost control and supply chain advantages.
- Outcomes research capabilities differentiated the company in the pharmaceutical market.
Ueber ROIX
Response Oncology, Inc., established in 1984 and based in Memphis, Tennessee, once operated as a comprehensive cancer management company. The company, along with its subsidiaries, provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers, under the direction of practicing oncologists. Additionally, Response Oncology owned the assets of and managed the non-medical aspects of oncology practices. The company also compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost-plus fee. Furthermore, Response Oncology conducted outcomes research on behalf of pharmaceutical manufacturers. However, as of May 20, 2002, the company liquidated substantially all of its operating assets. It anticipated that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002, effectively ceasing its primary business operations. Currently, Response Oncology, Inc. does not have significant operations.
Was das Unternehmen tut
- Formerly provided advanced cancer treatment services through outpatient facilities.
- Managed the non-medical aspects of oncology practices.
- Compounded and dispensed pharmaceuticals to oncologists.
- Conducted outcomes research for pharmaceutical manufacturers.
- Operated IMPACT Centers under the direction of practicing oncologists.
- Liquidated substantially all operating assets as of May 20, 2002.
- Currently has no significant operations.
Geschaeftsmodell
- Historically, Response Oncology generated revenue through cancer treatment services.
- Revenue was also derived from managing oncology practices.
- Pharmaceutical compounding and dispensing contributed to revenue streams.
- Outcomes research conducted for pharmaceutical manufacturers provided additional income.
Branchenkontext
Response Oncology, Inc. formerly operated within the medical care facilities industry, which involves providing services such as cancer treatment through outpatient facilities. The industry is characterized by technological advancements in treatment methods, evolving regulatory landscapes, and a focus on patient care. However, given that Response Oncology liquidated its assets in 2002, its current relevance to the industry is limited. Competitors in this space include companies like GNRS, LHRP, QMED, RFCS, and SYNI, which continue to operate and innovate within the healthcare sector.
Wichtige Kunden
- Practicing oncologists who directed IMPACT Centers.
- Patients receiving cancer treatment services.
- Pharmaceutical manufacturers seeking outcomes research.
- Oncology practices for which Response Oncology managed non-medical aspects.
Finanzdaten
Chart & Info
Response Oncology, Inc. (ROIX) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ROIX verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ROIX.
Kursziele
Wall-Street-Kurszielanalyse fuer ROIX.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ROIX auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Charles E. Sweet
Managing Employee
Charles E. Sweet currently manages 10 employees at Response Oncology, Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to ascertain his specific qualifications and experience in the healthcare industry or related fields. His role involves overseeing the remaining operations of the company following the liquidation of its assets.
Erfolgsbilanz: Due to the limited information available, it is difficult to assess Charles E. Sweet's track record at Response Oncology, Inc. The company liquidated its operating assets in 2002, and his role appears to be primarily focused on managing the remaining wind-down activities. Specific achievements or strategic decisions under his leadership cannot be determined based on the provided data.
ROIX OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often include those of distressed companies, shell companies, and companies with limited or no public information. Companies on the OTC Other tier may not meet minimum financial standards or have chosen not to comply with OTCQX or OTCQB requirements. Investing in securities on this tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited or no financial disclosure.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- High price volatility.
- Illiquidity and difficulty in trading shares.
- Verify the company's legal status and registration.
- Attempt to obtain any available financial statements.
- Assess the company's management team and their experience.
- Research any legal or regulatory issues involving the company.
- Understand the company's business model and its prospects.
- Evaluate the liquidity of the stock and the potential for trading difficulties.
- Check for any available public filings or disclosures.
- Verify the company's contact information and physical address.
- Assess the company's website and online presence.
- Look for any independent audits or certifications.
- Research the background of the company's management team.
ROIX Healthcare Aktien-FAQ
What are the key factors to evaluate for ROIX?
Response Oncology, Inc. (ROIX) currently holds an AI score of 46/100, indicating low score. Key strength: Historical presence in cancer management.. Primary risk to monitor: Potential: Lack of liquidity in the OTC market.. This is not financial advice.
How frequently does ROIX data refresh on this page?
ROIX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ROIX's recent stock price performance?
Recent price movement in Response Oncology, Inc. (ROIX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Historical presence in cancer management.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ROIX overvalued or undervalued right now?
Determining whether Response Oncology, Inc. (ROIX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ROIX?
Before investing in Response Oncology, Inc. (ROIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ROIX to a portfolio?
Potential reasons to consider Response Oncology, Inc. (ROIX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Historical presence in cancer management.. Additionally: Established network of IMPACT Centers (prior to liquidation).. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ROIX?
Yes, most major brokerages offer fractional shares of Response Oncology, Inc. (ROIX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ROIX's earnings and financial reports?
Response Oncology, Inc. (ROIX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ROIX earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may not be complete.
- The company's financial and operational status may have changed since the last available information.
- OTC market investments carry significant risks.